Abeona Therapeutics (ABEO) Cash from Investing Activities (2011 - 2026)

Abeona Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 17.8% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $105.8 million, a 488.75% increase from a year earlier, with the FY2025 full-year figure at $105.0 million, up 367.66% from the prior year.
• Cash from Investing Activities eased to $5.0 million in Q1 2026 per ABEO's latest filing, from $9.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $155.9 million in Q2 2025 and bottomed at -$64.6 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $1.6 million (2022), against an average of $2.8 million.
• Biggest YoY gain for Cash from Investing Activities was 472.75% in 2023; the steepest drop was 1236.63% in 2023.
• Year by year, Cash from Investing Activities stood at -$25.3 million in 2022, then surged by 145.59% to $11.5 million in 2023, then jumped by 63.73% to $18.9 million in 2024, then plunged by 49.39% to $9.6 million in 2025, then slumped by 48.05% to $5.0 million in 2026.
• Per Business Quant, the three latest ABEO Cash from Investing Activities figures stand at $5.0 million (Q1 2026), $9.6 million (Q4 2025), and -$64.6 million (Q3 2025).